Certificate of Analysis for NR-52150

Acinetobacter baumannii, Strain MRSN 918

Catalog No. NR-52150

This reagent is the tangible property of the U.S. Government.

Product Description:

Acinetobacter baumannii (A. baumannii), strain MRSN 918 was isolated in 2008 from a human wound sample in the USA as part of a global surveillance program. *A. baumannii*, strain MRSN 918 was deposited as multi-locus sequence type (MLST) ST 2, sensitive to colistin and tobramycin and resistant to amikacin, ampicillin/sulbactam, cefepime, ceftazidime, ceftriaxone, ciprofloxacin, gentamicin, imipenem, levofloxacin, meropenem, tetracycline and trimethoprim/sulfamethoxazole. NR-52150 lot 70057713 was produced by inoculation of BEI Resources seed lot 70038254 into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

Lot: 70057713 **Manufacturing Date: 13JAN2023**

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: Contact@BEIResources.org. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-negative rods	Gram-negative rods
Colony morphology	Report results	Circular, convex, entire, smooth and cream (Figure 1)
Growth at 44°C ± 2°C[1] 1 day in an aerobic atmosphere on Tryptic Soy agar	Growth	Growth
Motility Hardy Diagnostics™ Motility Test Medium w/TTC Indicator for 1 day at 37°C in an aerobic atmosphere	Report results	Non-motile
VITEK® MS (MALDI-TOF)	*A. baumannii*	*A. baumannii* (99.9%)
Antibiotic Susceptibility Profile[2,3]		
Amikacin	Resistant	Resistant (> 256 µg/mL)
Ampicillin/sulbactam	Resistant	Intermediate (12 to 16 µg/mL)[4]
Cefepime	Resistant	Resistant (32 µg/mL)
Ceftriaxone	Resistant	Resistant (≥ 64 µg/mL)
Ceftazidime	Resistant	Resistant (≥ 64 µg/mL)
Ciprofloxacin	Resistant	Resistant (≥ 4 µg/mL)
Gentamicin	Resistant	Resistant (≥ 16 µg/mL)
Imipenem	Resistant	Resistant (> 32 µg/mL)
Levofloxacin	Resistant	Resistant (≥ 8 µg/mL)
Meropenem	Resistant	Resistant (≥ 16 µg/mL)
Trimethoprim/sulfamethoxazole	Resistant	Resistant (> 32 µg/mL)
Tobramycin	Sensitive	Sensitive (≤ 1 µg/mL)
Tetracycline	Resistant	Resistant (≥ 16 µg/mL)
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene (~ 1380 base pairs)	≥ 99% sequence identity to *A. baumannii*, strain MRSN 918 (GenBank: VHDT01000102.1)	100% sequence identity to *A. baumannii*, strain MRSN 918 (GenBank: VHDT01000102.1)
Purity 7 days at 37°C in an aerobic atmosphere with and without 5% CO_2 on Tryptic Soy agar	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology

BEI Resources
www.beiresources.org
E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898

Certificate of Analysis for NR-52150

TEST	SPECIFICATIONS	RESULTS
Viability	Growth	Growth

[1]Growth at 44°C differentiates *A. baumannii* from *A. calcoaceticus* and *A. pittii*, which do not grow at 44°C.
[2]Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)
[3]Antibiotic susceptibility was tested using a combination of VITEK®2 GN81 and E-test strips.
[4]*A. baumannii*, strain MRSN 918 was deposited as being resistant to ampicillin/sulbactam, but showed MICs of 12 µg per mL and 16 µg per mL (interpreted as intermediately resistant) for lot 70057713 during QC testing. The first lot, 70038246, showed MICs of 48 to 64 µg/mL, which are interpreted as resistant.

Figure 1: Colony Morphology

/Sonia Bjorum Brower/
Sonia Bjorum Brower 12 JUN 2023
Technical Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

Support Provided by NIAID

BEI Resources
www.beiresources.org
E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898